PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
22.24%
ROE below 50% of CRVO's 220.28%. Michael Burry would look for signs of deteriorating business fundamentals.
-98.77%
Negative ROA while CRVO stands at 0.00%. John Neff would check for structural inefficiencies or mispriced assets.
-160.89%
Negative ROCE while CRVO is at 73.52%. Joel Greenblatt would look for capital misallocation or cyclical downturn.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.